2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Pathology, Serologic Tests, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Apoptosis, Pathogenesis, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, GVHD, Neutropenia, Infectious Diseases, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

5846 Clonotypic analysis of spatially resolved tcrb and IGH sequences in graft-vs.-host disease

Yuta Kiami, Samuel Legg2, Kathleen Ensbey3, Tomoko Sekiguchi4, Annalyssa N Long5, David Sierra6, Paul Kong7, Anna E Elz8, Francesco Mazziotta, MD, PhD9, Aude Chapuis, MD10, Evan W Newell, PhD11, Geoff R Hill, MD12, Philip Bradley, PhD13, Albert C Yeh, MD14
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States
11 Fred Hutchinson Cancer Center, Seattle, Washington, United States
12 Fred Hutchinson Cancer Center, Seattle, Washington, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States
14 Fred Hutchinson Cancer Center, Seattle, Washington, United States

Background:

Advances in spatial transcriptomics have resolved single-cell anatomy in multiple tissue types. However, insight into spatial distribution of clonotypic T and B-cell responses remains limited due to challenges in applying adaptive repertoire sequencing to formalin-fixed paraffin-embedded (FFPE) tissue due to crosslinking and degradation of nucleic acid. Here, we utilize an adaptive sequencing platform (Singular Genomics, Direct-seq) that enables in situ sequencing of the CDR3 region of the TCRB and IGH repertoires, alongside standard probe-based gene expression profiling. As increasing error rates from sequencing cycles arise from out-of-plane imaging, we developed an error correction algorithm and a weighted sequence-distance score to account for platform-based read errors. We hypothesize that this platform would augment characterization of the alloreactive T cell response by linking clonal expansion with spatial colocalization in patients with graft-vs.-host disease (GvHD).

Methods:

Thirty-one endoscopic biopsies from 16 patients were obtained, including 23 patient biopsy samples at the time of acute GvHD rule-out (median [range] 42 [20-132] days post-transplant), 3 healthy controls, 2 pre-transplant, and 3 additional follow-up samples. Anatomical compartments include upper GI (duo N=8, stomach N=4) and lower GI (colon N=18, cecum N=1) tracts. Out of the 23 patients, we stratified acute GvHD severity into two categories: low (none N=8, minimal N=3, mild N=3) or high (mild/mod N=1, mod N=1, mod/severe N=2, and severe N=5). For each tissue, three serial, 5-micron FFPE tissue layers were obtained for spatial transcriptomics, including in situ VDJ sequencing (Direct-seq, layers 1 and 3), and gene expression using a dedicated human colon 318-gene panel (GEX, layer 2). In situ per-position sequencing error rate was determined by aligning Direct-seq CDR3 sequences to TCR clones identified in single-cell sequencing data. An exponential error-rate function was fitted and used to generate a weighted distance by assuming sequence equivalence between reads and summing negative-log probabilities of each mismatch site. Average-linkage agglomerative clustering (ALINK) was then applied to call clones in the GvHD set.

Results:

We first performed standard gene expression analysis using the GEX layer. Amongst the 18 cell types recovered (N=372,284), 59,101 and 47,647 were T and plasma cells. We demonstrated that depletion of goblet cells in lower GI samples was seen in high vs. low GvHD severity (4.3% vs. 15%, FDR < 0.01). There was also a shift in colonocyte compartment in patients with higher vs. lower GvHD severity represented by a trend towards an increased GPX2+/MHCII+ colonocyte population (6.4% vs. 1.2%). An increased proportion of T- (17 vs. 11%), plasma cell (13% vs. 8.9%), and macrophages (7.5% vs. 4.3%) in patients was also seen in patients with higher GvHD severity that did not reach statistical significance. We next performed VDJ analysis using our weighted-distance model on the Direct-seq layers using a total of 12,214 IGH and 715 TCRB CDR3 reads captured across the gut tissue sections. Out of this pool, there was a larger fraction of expanded TCRB clonotypes (2 or greater clonotypes) in high vs. low GvHD severity (mean fraction expanded 5.8% [total 8/138] vs. 0.7% [total 1/139], p=0.019), a pattern not seen for IGH clonotypes (p=0.54). Expanded TCRB and IGH clonotypes are in closer proximity with each other compared to non-expanded clonotypes (TCRB: 577mm vs. 842mm; IGH: 946mm vs. 1008mm; p=0.01). Finally, we combined both GEX and Direct-seq layers to ascertain differences between the neighborhoods of expanded clonotypes. Expanded clonotypes were more likely to be in the lamina propria vs. epithelium, as nearest neighbors included macrophages, plasma cells, T cells, and stromal cells rather than epithelial cells, although a trend was seen between co-localization of expanded TCR clonotypes with GPX2+/MHCII+/CD74+ colonocytes compared to non-expanded clonotypes.

Conclusions:

We demonstrate the feasibility of in situ VDJ sequencing on FFPE samples to spatially identify clonally expanded T- and plasma cells in gut GvHD tissue. Sensitivity of direct seq reads to detect individual cells compared to segmented cells based on gene expression was low (~25.6% for plasma cells and ~1.2% for T cells). However, we were able to capture expanded clonotypes in both compartments and demonstrate an increase in spatial proximity.

Yuta Kiami: No relevant conflicts of interest to declare.